117 related articles for article (PubMed ID: 12365478)
1. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.
van Outryve S; Schrijvers D; van den Brande J; Wilmes P; Bogers J; van Marck E; Vermorken JB
Neth J Med; 2002 Jun; 60(5):216-22. PubMed ID: 12365478
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study.
Kanno M; Nakamura S; Uotani C; Taniya T; Mura T; Bando H; Kawahara F; Tsugawa K; Noguchi M
J Chemother; 1999 Oct; 11(5):396-401. PubMed ID: 10632387
[TBL] [Abstract][Full Text] [Related]
4. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
5. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Hirvikoski PP; Kumpulainen EJ; Johansson RT
Breast Cancer Res Treat; 1997 Jul; 44(3):269-74. PubMed ID: 9266107
[TBL] [Abstract][Full Text] [Related]
6. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
Kumpulainen EJ; Hirvikoski PP; Johansson RT
Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
[TBL] [Abstract][Full Text] [Related]
8. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen).
Locatelli M; Colleoni M; Noberasco C; Nolé F; Orlando L; Munzone E; Peruzzotti G; Goldhirsch A
Ann Oncol; 1999 Nov; 10(11):1394-5. PubMed ID: 10631475
[No Abstract] [Full Text] [Related]
9. Salvage chemotherapy with mitoxantrone and mitomycin with or without methotrexate in advanced breast cancer.
Astone A; Cassano A; Fontana T; Noviello MR; Pozzo C; Barone C
Anticancer Drugs; 1992 Oct; 3(5):471-3. PubMed ID: 1450440
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
12. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
14. Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
Bezwoda WR; Hesdorffer CS; Dansey RD
S Afr Med J; 1987 Oct; 72(7):465-7. PubMed ID: 3660150
[TBL] [Abstract][Full Text] [Related]
15. Surgical adjuvant chemotherapy for breast cancer: a comparison of CMF and CAF regimens.
Babar AM
J Pak Med Assoc; 1991 Dec; 41(12):293-6. PubMed ID: 1824559
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.
Merlini L; Secondo V; Mammoliti S; Bellotti P; Castello C; Gallo L
Anticancer Res; 1994; 14(3B):1423-6. PubMed ID: 8067717
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
[TBL] [Abstract][Full Text] [Related]
18. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
19. The use of mitoxantrone in the treatment of breast cancer.
Hainsworth JD
Semin Oncol; 1995 Feb; 22(1 Suppl 1):17-20. PubMed ID: 7863347
[No Abstract] [Full Text] [Related]
20. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
